Access to biologic therapies in Canada for children with juvenile idiopathic arthritis

Journal of Rheumatology

Volumn 39, Issue 9, 2012, Pages 1875-1879

  Leblanc, Claire M A ^a   Lang, Bianca ^b   Bencivenga, Alma ^c   Chetaille, Anne Laure ^d   Dancey, Paul ^e,f   Dent, Peter ^g   Miettunen, Paivi ^h   Oen, Kiem ⁱ   Rosenberg, Alan ^j   Roth, Johannes ^k   Scuccimarri, Rosie ^a   Tse, Shirley M L ^l   Benseler, Susanne ^l   Cabral, David A ^c   Campillo, Sarah ^a   Chédeville, Gaëlle ^a   Duffy, Ciaran M ^k   Duffy, Karen Watanabe ^a   Haddad, Elie ^m   Huber, Adam M ^b   Laxer, Ronald ^l   Levy, Deborah ^l   Johnson, Nicole ^h   Ramsey, Suzanne ^b   Shiff, Natalie ^j   Schmeling, Heinrike ^h   Schneider, Rayfel ^l   Stringer, Elizabeth ^b   Yeung, Rae S M ^h   Tucker, Lori B ^c   more..

^a MCGILL UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f Memorial University   (Australia)

^g MCMASTER UNIVERSITY   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

^j UNIVERSITY OF SASKATCHEWAN   (Canada)

^k UNIVERSITY OF OTTAWA   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

^m UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

Drug accessibility Canada; Juvenile idiopathic arthritis biologic products

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; ETANERCEPT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

ARTICLE; CANADA; CHILD; CRITERION VARIABLE; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH ECONOMICS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; REIMBURSEMENT; SOCIAL STATUS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL AGENTS; CANADA; CHILD; FEMALE; HEALTH CARE SURVEYS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; SEVERITY OF ILLNESS INDEX;

EID: 84865735186     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120089     Document Type: Article

References (16)

1. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al, for the Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
2. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106.
3. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: A randomized, double blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
4. Lovell DJ, Ruperto N, Jung L, Reiff A, Nemcova D, Jarosova K, et al. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results [abstract]. Arthritis Rheum 2006;54 Suppl:S303.
5. Otten MH, Prince FH, Ten Cate R, van Rossum MA, Twilt M, Hoppenreijs EP, et al. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: Are they effective? Ann Rheum Dis 2011;70:337-40.
6. Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: Safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009;28:129-37.
7. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset idiopathic arthritis: A randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
8. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, Morgan DeWitt E, et al. 2011 American College of Rheumatology recommendations of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-84.
9. Sulpice M, Job Deslandre C, Quartier P. Efficacy and safety of TNF alpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine 2009;76:24-7.
10. Tse SML, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005;52:2103-8.
11. Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50.
12. Tynjälä P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology 2008;47:339-44.
13. Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 2008;23:413-9.
14. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: A report of four pediatric patients. Arthritis Rheum 2007;56:3107-11.
15. Patel AM, Lehman TAJ. Rituximab for severe refractory pediatric Wegener granulomatosis. J Clin Rheumatol 2008;14:278-80.
16. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal onset multisystem inflammatory disease responsive to interleukin-1α inhibition. N Engl J Med 2006;355:581-92.